Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.

@article{Isotani2008EffectOT,
  title={Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.},
  author={Mayu Isotani and Naoya Ishida and Masahiro Tominaga and Kunihiro Tamura and Hiroko Yagihara and Satoshi Ochi and Ryoji Kato and Tetsuya Kobayashi and Mamoru Fujita and Yasuhito Fujino and Asuka Setoguchi and Koji Ono and Tsukimi Washizu and M Bonkobara},
  journal={Journal of veterinary internal medicine},
  year={2008},
  volume={22 4},
  pages={985-8}
}
BACKGROUND Imatinib mesylate is a small molecule targeted at dysregulated protein-tyrosine kinase. Mutation of c-kit exon 11, which induces constitutive phosphorylation of KIT, is one of the mechanisms for the development or progression of mast cell tumor (MCT) in dogs. The purpose of this study was to examine the therapeutic potential of imatinib mesylate in canine MCT. HYPOTHESIS Imatinib mesylate has activity against MCT in dogs, and response to treatment can be correlated to presence of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

  • GD Demetri, M von Mehren, CD Blanke
  • N Engl J Med
  • 2002
1 Excerpt

Similar Papers

Loading similar papers…